Business Context and Reporting Period
This Form 8-K was filed by BioRestorative Therapies, Inc. (NASDAQ: BRTX) on July 11, 2023. The filing reports the entry into a material definitive agreement for a registered direct offering of common stock.
Key Financial Metrics
- Offering Size: 685,033 shares of common stock.
- Offering Price: $3.03 per share.
- Gross Proceeds: Approximately $2.1 million.
- Placement Agent Fee: 6.0% of gross proceeds.
- Expense Reimbursement: Up to $60,000 for legal and out-of-pocket expenses.
- Expected Closing Date: On or about July 13, 2023.
Material Changes
The primary material change is the execution of a securities purchase agreement with institutional buyers and accredited investors. This transaction represents a new equity financing event intended to increase the company's cash reserves. No prior comparable period financial data is provided in this specific filing.
Guidance, Outlook, and Use of Proceeds
Management intends to use the net proceeds from the offering for the following purposes:
- Clinical trials for the lead cell therapy candidate, BRTX-100.
- Pre-clinical research and development for the metabolic ThermoStem Program.
- General corporate purposes and working capital.
The filing does not provide specific forward-looking financial guidance, risk factors, or contingencies beyond standard representations and warranties in the purchase agreement.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting fees and expenses.
- Confirm the dilution impact of the 685,033 new shares on existing shareholders.
- Review the full text of the Purchase Agreement (Exhibit 10.1) for specific covenants and termination provisions.
- Monitor subsequent filings for updates on the progress of the BRTX-100 clinical trials and ThermoStem Program.